Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 114.99M P/E - EPS this Y 13.90% Ern Qtrly Grth -
Income -113.45M Forward P/E -0.87 EPS next Y 26.70% 50D Avg Chg 2.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book 0.54 EPS next 5Y - 52W High Chg -31.00%
Recommedations 3.00 Quick Ratio 3.47 Shares Outstanding 38.44M 52W Low Chg 36.00%
Insider Own 1.75% ROA -47.53% Shares Float 27.11M Beta 2.91
Inst Own 63.76% ROE -84.57% Shares Shorted/Prior 1.65M/0.99M Price 3.03
Gross Margin - Profit Margin - Avg. Volume 257,546 Target Price 0.50
Oper. Margin - Earnings Date Nov 7 Volume 251,117 Change 4.48%
About Athira Pharma, Inc.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Athira Pharma, Inc. News
12/18/24 Athira Pharma Insider Ups Holding By 111% During Year
12/06/24 Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
11/08/24 Athira exploring strategic alternatives after Alzheimer’s failure
11/07/24 Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
11/04/24 US Penny Stocks: November 2024's Top Picks To Consider
10/22/24 Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
09/17/24 Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
09/05/24 Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
09/04/24 Athira’s stock topples after Alzheimer’s drug flops in Phase II/III trial
09/04/24 ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
09/04/24 Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
09/03/24 Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
08/23/24 Are Medical Stocks Lagging Athira Pharma (ATHA) This Year?
08/07/24 Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year?
08/01/24 Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
07/31/24 Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
07/10/24 Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
07/09/24 Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
06/30/24 retail investors who own 35% along with institutions invested in Athira Pharma, Inc. (NASDAQ:ATHA) saw increase in their holdings value last week
06/12/24 Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Gengos Andrew See Below See Below Jan 04 Sell 2.91 1,208 3,515 83,804 01/08/24
PERCEPTIVE ADVISORS LLC Director Director Dec 27 Buy 2.37 605,686 1,435,476 5,402,964 12/29/23
Gengos Andrew See Below See Below Jun 07 Buy 3.4 15,000 51,000 80,012 06/09/23
Gengos Andrew See Below See Below Jun 02 Buy 2.94 65,012 191,135 65,012 06/06/23
MOEBIUS HANS Chief Medical Office.. Chief Medical Officer Jun 02 Option 1.35 7,882 10,641 81,482 06/06/23
PICKERING GRANT Director Director Mar 29 Buy 2.4 25,000 60,000 25,783 03/31/23
JOHNSON JAMES A Director Director Mar 29 Buy 2.40 5,000 12,000 5,000 03/30/23
MILESON GLENNA Chief Financial Offi.. Chief Financial Officer Dec 28 Buy 2.85 50,000 142,500 159,930 12/30/22
Romano Kelly A Director Director Dec 02 Buy 3.29 30,000 98,700 38,315 12/06/22
CHURCH KEVIN Executive VP, Resear.. Executive VP, Research Oct 28 Option 1.35 3,700 4,995 61,395 10/31/22
MOEBIUS HANS Chief Medical Office.. Chief Medical Officer Oct 13 Option 1.35 7,881 10,639 60,836 10/17/22
PERCEPTIVE ADVISORS LLC Director Director Jun 29 Buy 2.99 1,371,362 4,100,372 4,797,278 07/01/22
MOEBIUS HANS Chief Medical Office.. Chief Medical Officer Jun 28 Buy 2.88 10,000 28,800 52,955 06/30/22
Worthington Mark General Counsel General Counsel Jun 22 Sell 2.69 2,614 7,032 19,097 06/24/22
MILESON GLENNA Chief Financial Offi.. Chief Financial Officer Jun 22 Sell 2.69 2,614 7,032 109,167 06/24/22
Litton Mark James Chief Executive Offi.. Chief Executive Officer Jun 22 Sell 2.69 7,960 21,412 128,555 06/24/22
Lenington Rachel Chief Operating Offi.. Chief Operating Officer Jun 22 Sell 2.69 4,193 11,279 5,807 06/24/22
CHURCH KEVIN Executive VP, Resear.. Executive VP, Research Jun 22 Sell 2.69 2,614 7,032 57,695 06/24/22
CHURCH KEVIN Executive VP, Resear.. Executive VP, Research Jun 08 Option 1.35 2,500 3,375 50,309 06/10/22
MILESON GLENNA Chief Financial Offi.. Chief Financial Officer Apr 12 Option 10.64 3,000 31,920 100,060 04/12/22
CHURCH KEVIN Executive VP, Resear.. Executive VP, Research Feb 18 Option 1.19 3,152 3,751 47,566 02/18/22